Literature DB >> 17054677

Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells.

K L Morris1, J A Adams, J A Liu.   

Abstract

The effect of gemtuzumab ozogamicin (GO) alone, or combined with low-dose cytarabine or etoposide, on the proliferation of acute myeloid leukaemia blast cells in vitro was investigated. GO alone induced a dose-dependent inhibition of proliferation although an increase in apoptosis was only seen in a minority of patients. A correlation was found between PgP function and GO sensitivity but not between CD33 or PgP expression and GO. Combinations of GO with varying concentrations of cytarabine or etoposide were additive in inhibiting proliferation, reducing cell viability and increasing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054677     DOI: 10.1111/j.1365-2141.2006.06326.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  C D Godwin; R P Gale; R B Walter
Journal:  Leukemia       Date:  2017-06-13       Impact factor: 11.528

2.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

Review 3.  Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Authors:  Andrew J Cowan; George S Laszlo; Elihu H Estey; Roland B Walter
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

4.  Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.

Authors:  Mays Jawad; Ning Yu; Claire Seedhouse; Karuna Tandon; Nigel H Russell; Monica Pallis
Journal:  BMC Cancer       Date:  2012-09-26       Impact factor: 4.430

5.  ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.

Authors:  Roya Rafiee; Lata Chauhan; Todd A Alonzo; Yi-Cheng Wang; Ahlam Elmasry; Michael R Loken; Jessica Pollard; Richard Aplenc; Susana Raimondi; Betsy A Hirsch; Irwin D Bernstein; Alan S Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Blood Cancer J       Date:  2019-05-21       Impact factor: 11.037

6.  Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.

Authors:  Saveria Capria; Silvia Maria Trisolini; Clara Minotti; Caterina Stefanizzi; Luisa Cardarelli; Claudio Cartoni; Daniela Diverio; Maria Stefania De Propris; Marco Mancini; Alessandra Micozzi; Robin Foà; Giovanna Meloni
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-11-06       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.